<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238147</url>
  </required_header>
  <id_info>
    <org_study_id>6227</org_study_id>
    <secondary_id>UWCC-UW-6227</secondary_id>
    <secondary_id>AVENTIS-UW-03031</secondary_id>
    <secondary_id>ROCHE-UW-03031</secondary_id>
    <secondary_id>UW-03031</secondary_id>
    <secondary_id>UWCC-04-2311-D-01</secondary_id>
    <secondary_id>CDR0000445238</secondary_id>
    <nct_id>NCT00238147</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer</brief_title>
  <official_title>Phase I Trial With Weekly Docetaxel, Capecitabine and Carboplatin as Induction Chemotherapy Followed by Concomitant Capecitabine and Radiotherapy in Patients With Locally Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, carboplatin, and capecitabine, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Capecitabine&#xD;
      may also make tumor cells more sensitive to radiation therapy. Giving combination&#xD;
      chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the&#xD;
      amount of normal tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when&#xD;
      given together with carboplatin and capecitabine followed by chemoradiotherapy in treating&#xD;
      patients who are undergoing surgery for locally advanced esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of docetaxel when&#xD;
           administered with carboplatin and capecitabine as neoadjuvant induction therapy in&#xD;
           patients with locally advanced esophageal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the clinical and pathological response in these patients treated with&#xD;
           neoadjuvant induction therapy comprising docetaxel, carboplatin, and capecitabine&#xD;
           followed by chemoradiotherapy with capecitabine.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of docetaxel.&#xD;
&#xD;
        -  Induction therapy: Patients receive docetaxel IV and carboplatin IV over 30-60 minutes&#xD;
           on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats&#xD;
           every 28 days for 2 courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Approximately 7 days after completion of induction therapy, patients proceed to&#xD;
      chemoradiotherapy.&#xD;
&#xD;
        -  Chemoradiotherapy: Patients receive oral capecitabine twice daily on days 1-42 and&#xD;
           undergo radiotherapy once daily, 5 days a week, on days 1-40.&#xD;
&#xD;
        -  Surgery: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo&#xD;
           surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed esophageal or gastroesophageal junction cancer&#xD;
&#xD;
               -  Locally advanced disease, meeting 1 of the following staging criteria:&#xD;
&#xD;
                    -  T3, N0, M0 disease&#xD;
&#xD;
                    -  Any T, N1, M0 disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Alkaline phosphatase (AP) normal AND AST/ALT ≤ 5 times upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  AP ≤ 2.5 times ULN AND AST/ALT ≤ 1.5 times ULN&#xD;
&#xD;
               -  AP ≤ 5 times ULN AND AST/ALT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 80 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No other uncontrolled clinically significant cardiac disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to swallow tablets&#xD;
&#xD;
          -  Intact upper gastrointestinal tract&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No history of unanticipated severe reaction to fluoropyrimidine&#xD;
&#xD;
          -  No known hypersensitivity to fluorouracil&#xD;
&#xD;
          -  No severe hypersensitivity reaction to docetaxel or other drugs formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
          -  No serious infection that requires continuous antibiotic therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No history of serious psychiatric illness that would preclude study compliance or&#xD;
             giving informed consent&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 28 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent warfarin for active anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sujata Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rao S, Oelschlager BK, Koh WJ, et al.: Phase I trial with weekly docetaxel, capecitabine and carboplatin followed by concomitant capecitabine and radiotherapy in patients with locally advanced esophageal cancer. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-123, 2008.</citation>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

